A new bluetongue event has converted animal-health status into an immediate trade and certification problem for cattle and ruminant-germinal-product movements.

A bluetongue virus serotype 3 (BTV-3) detection in Latvia has rapidly become a trade issue for ruminant businesses rather than solely a veterinary-surveillance event. The UK government said Latvia confirmed BTV-3 outbreaks in cattle to the World Organisation for Animal Health on 26 October. Latvia consequently lost its bluetongue-free status, and Great Britain changed its import conditions three days later.

The change is unusually consequential because it affects the practical ability to certify movements. From 29 October, the entry for Latvia on Great Britain's list of European Union (EU) and European Free Trade Association (EFTA) countries approved to export live ungulates carries Supplementary Guarantee A. The guarantee requires live ruminants exported from Latvia to Great Britain to be vaccinated against every BTV serotype circulating in the country.

But the government says BTV-3 vaccines authorised in the European Union cannot currently be used for trade purposes because information on the duration of immunity is lacking. The result is not merely an additional document or inspection step: imports of live ruminants from Latvia cannot be certified for export to Great Britain under the relevant certificate conditions. Ruminant germinal products are also affected, with imports now needing to meet BTV testing requirements in the applicable health certificates and import-information note.

For breeding, dairy and beef supply chains, that distinction matters. A disease finding at cattle level can curtail access to live-animal trade and complicate the movement of semen, embryos and other germinal material even where no broad consumer-food restriction is described. Buyers, exporters, breeding companies and veterinarians must now factor certification feasibility into dispatch schedules and contracts, rather than assuming that a vaccinated animal can automatically move.

The development also illustrates the commercial value of vaccine evidence beyond availability. A vaccine may be authorised for animal-health use while still falling short of the evidence needed to support a particular trade certificate. Until the immunity-duration gap is resolved or requirements change, the immediate pressure falls on contingency sourcing, movement planning and the testing and documentation capacity around Latvian ruminant genetics.

For more information: Department for Environment, Food & Rural Affairs and Animal & Plant Health Agency